Last reviewed · How we verify
AST-726 High dose — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
AST-726 High dose (AST-726 High dose) — Ariston Pharmaceuticals, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| AST-726 High dose TARGET | AST-726 High dose | Ariston Pharmaceuticals, Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- AST-726 High dose CI watch — RSS
- AST-726 High dose CI watch — Atom
- AST-726 High dose CI watch — JSON
- AST-726 High dose alone — RSS
Cite this brief
Drug Landscape (2026). AST-726 High dose — Competitive Intelligence Brief. https://druglandscape.com/ci/ast-726-high-dose. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing